Share Price and Basic Stock Data
Last Updated: January 21, 2026, 7:59 pm
| PEG Ratio | 0.81 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Fredun Pharmaceuticals Ltd operates within the pharmaceuticals industry and has demonstrated a consistent upward trajectory in its revenue. For the fiscal year ending March 2025, the company reported sales of ₹456 Cr, reflecting a significant increase from ₹348 Cr in March 2024 and ₹275 Cr in March 2023. The trailing twelve months (TTM) revenue stood at ₹535 Cr, suggesting a robust growth momentum. Quarterly sales have shown variability, with the most recent quarter ending September 2023 recording sales of ₹81.98 Cr, which increased to ₹87.00 Cr by December 2023. This trend indicates a potential recovery following a dip to ₹62.05 Cr in June 2023. Overall, Fredun’s revenue growth aligns with the broader pharmaceutical sector’s expansion, driven by increasing healthcare demand, although fluctuations in quarterly performance highlight the operational challenges the company faces.
Profitability and Efficiency Metrics
The profitability metrics for Fredun Pharmaceuticals demonstrate a mixed yet generally positive performance. The net profit for the fiscal year ending March 2025 was reported at ₹21 Cr, an increase from ₹16 Cr in March 2024 and ₹11 Cr in March 2023. The operating profit margin (OPM) for the most recent quarter stood at 15.37%, while the annual OPM for March 2025 was recorded at 12.14%. Although the OPM reflects a stable operational efficiency, the company’s interest coverage ratio (ICR) of 2.46x indicates that Fredun has a moderate ability to cover its interest obligations, with interest expenses rising to ₹22 Cr by March 2025. Furthermore, the return on equity (ROE) stands at 15.8%, showcasing a satisfactory return for shareholders, but it remains crucial to monitor the trends in operating income and expenses as they will significantly impact overall profitability.
Balance Sheet Strength and Financial Ratios
Fredun Pharmaceuticals has exhibited a solid balance sheet, albeit with some concerns regarding its debt levels. As of March 2025, total borrowings amounted to ₹171 Cr against reserves of ₹153 Cr, suggesting a reliance on external financing. The debt-to-equity ratio stood at 1.18x, indicating a higher leverage compared to industry norms. However, the company’s current ratio of 1.31x reflects adequate liquidity to meet short-term obligations. Furthermore, the book value per share has steadily increased, reaching ₹299.47 by March 2025, which contributes positively to investor confidence. The return on capital employed (ROCE) was reported at 31.78%, indicating effective utilization of capital for generating profits. These metrics suggest that while Fredun is managing its resources efficiently, the rising debt levels warrant close attention and could pose risks if not managed prudently.
Shareholding Pattern and Investor Confidence
Fredun Pharmaceuticals’ shareholding structure reveals a significant level of promoter ownership at 48.93%, which is indicative of strong management control and alignment with shareholder interests. The public holds 49.46% of the shares, reflecting a healthy distribution among retail investors, while foreign institutional investors (FIIs) hold a mere 0.01%, suggesting limited foreign interest in the stock. Domestic institutional investors (DIIs) account for 1.61%, showing some institutional backing but still leaving room for improvement in attracting institutional investment. The total number of shareholders has increased to 8,120, up from 6,313 in September 2023, indicating growing retail interest. This pattern of shareholding, coupled with a stable dividend payout of ₹0.70 per share, enhances investor confidence in the company, although the low institutional presence may limit price support in volatile market conditions.
Outlook, Risks, and Final Insight
Looking ahead, Fredun Pharmaceuticals faces both opportunities and challenges. The increasing demand for pharmaceuticals positions the company favorably for growth; however, the reliance on debt financing poses a risk, particularly if interest rates rise or if there are unexpected operational challenges. Additionally, fluctuations in quarterly sales can impact cash flow and operational stability. Strengths include a solid increase in revenue and profitability metrics, alongside a consistent improvement in shareholder value, as evidenced by the rising EPS of ₹44.83 for March 2025. Conversely, risks such as high leverage and limited institutional investor interest could hinder long-term growth. In scenarios where operational improvements are realized, coupled with effective debt management, Fredun could enhance its market position significantly, whereas failure to address these risks may adversely affect its financial health and investor sentiment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 120 Cr. | 95.1 | 205/84.3 | 26.5 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,425 Cr. | 315 | 479/192 | 70.9 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.3 Cr. | 43.5 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 59.6 Cr. | 40.7 | 41.6/17.0 | 142 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,407.85 Cr | 1,083.54 | 50.39 | 202.18 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 70.32 | 77.96 | 79.81 | 62.05 | 81.98 | 87.00 | 118.03 | 78.82 | 107.35 | 102.70 | 167.41 | 119.85 | 145.30 |
| Expenses | 63.52 | 70.66 | 67.55 | 54.44 | 72.37 | 76.48 | 106.87 | 68.34 | 93.40 | 89.48 | 149.97 | 102.86 | 122.97 |
| Operating Profit | 6.80 | 7.30 | 12.26 | 7.61 | 9.61 | 10.52 | 11.16 | 10.48 | 13.95 | 13.22 | 17.44 | 16.99 | 22.33 |
| OPM % | 9.67% | 9.36% | 15.36% | 12.26% | 11.72% | 12.09% | 9.46% | 13.30% | 12.99% | 12.87% | 10.42% | 14.18% | 15.37% |
| Other Income | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Interest | 1.86 | 1.95 | 3.55 | 2.61 | 2.90 | 3.77 | 4.37 | 3.91 | 5.31 | 5.00 | 8.15 | 6.53 | 7.73 |
| Depreciation | 0.72 | 0.74 | 0.70 | 0.92 | 0.94 | 0.99 | 0.96 | 1.05 | 1.06 | 1.09 | 1.25 | 1.42 | 1.60 |
| Profit before tax | 4.22 | 4.61 | 8.01 | 4.08 | 5.77 | 5.76 | 5.83 | 5.52 | 7.58 | 7.13 | 8.04 | 9.04 | 13.00 |
| Tax % | 25.12% | 25.16% | 51.44% | 41.18% | 31.72% | 26.74% | 13.38% | 25.18% | 43.54% | 25.25% | 12.06% | 25.11% | 25.15% |
| Net Profit | 3.15 | 3.46 | 3.89 | 2.40 | 3.94 | 4.22 | 5.06 | 4.13 | 4.27 | 5.33 | 7.07 | 6.77 | 9.73 |
| EPS in Rs | 7.07 | 7.66 | 8.58 | 5.24 | 8.41 | 8.98 | 10.76 | 8.75 | 9.04 | 11.29 | 14.97 | 14.34 | 20.61 |
Last Updated: January 8, 2026, 11:04 am
Below is a detailed analysis of the quarterly data for Fredun Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 145.30 Cr.. The value appears strong and on an upward trend. It has increased from 119.85 Cr. (Jun 2025) to 145.30 Cr., marking an increase of 25.45 Cr..
- For Expenses, as of Sep 2025, the value is 122.97 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 102.86 Cr. (Jun 2025) to 122.97 Cr., marking an increase of 20.11 Cr..
- For Operating Profit, as of Sep 2025, the value is 22.33 Cr.. The value appears strong and on an upward trend. It has increased from 16.99 Cr. (Jun 2025) to 22.33 Cr., marking an increase of 5.34 Cr..
- For OPM %, as of Sep 2025, the value is 15.37%. The value appears strong and on an upward trend. It has increased from 14.18% (Jun 2025) to 15.37%, marking an increase of 1.19%.
- For Other Income, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Interest, as of Sep 2025, the value is 7.73 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6.53 Cr. (Jun 2025) to 7.73 Cr., marking an increase of 1.20 Cr..
- For Depreciation, as of Sep 2025, the value is 1.60 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.42 Cr. (Jun 2025) to 1.60 Cr., marking an increase of 0.18 Cr..
- For Profit before tax, as of Sep 2025, the value is 13.00 Cr.. The value appears strong and on an upward trend. It has increased from 9.04 Cr. (Jun 2025) to 13.00 Cr., marking an increase of 3.96 Cr..
- For Tax %, as of Sep 2025, the value is 25.15%. The value appears to be increasing, which may not be favorable. It has increased from 25.11% (Jun 2025) to 25.15%, marking an increase of 0.04%.
- For Net Profit, as of Sep 2025, the value is 9.73 Cr.. The value appears strong and on an upward trend. It has increased from 6.77 Cr. (Jun 2025) to 9.73 Cr., marking an increase of 2.96 Cr..
- For EPS in Rs, as of Sep 2025, the value is 20.61. The value appears strong and on an upward trend. It has increased from 14.34 (Jun 2025) to 20.61, marking an increase of 6.27.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:43 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 21 | 25 | 42 | 57 | 60 | 97 | 113 | 134 | 222 | 275 | 348 | 456 | 535 |
| Expenses | 20 | 24 | 38 | 53 | 54 | 87 | 104 | 126 | 208 | 247 | 310 | 401 | 465 |
| Operating Profit | 1 | 2 | 4 | 3 | 6 | 10 | 8 | 8 | 14 | 28 | 38 | 55 | 70 |
| OPM % | 7% | 7% | 9% | 6% | 10% | 11% | 7% | 6% | 6% | 10% | 11% | 12% | 13% |
| Other Income | 0 | 0 | 1 | 2 | 0 | 0 | 1 | 1 | 2 | 2 | 1 | -0 | 0 |
| Interest | 1 | 1 | 2 | 2 | 2 | 3 | 4 | 4 | 5 | 9 | 14 | 22 | 27 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 4 | 4 | 5 |
| Profit before tax | 0 | 1 | 2 | 2 | 3 | 6 | 2 | 3 | 9 | 18 | 21 | 28 | 37 |
| Tax % | 47% | 52% | 42% | 36% | 34% | 28% | 24% | 37% | 26% | 38% | 27% | 26% | |
| Net Profit | 0 | 0 | 1 | 1 | 2 | 4 | 2 | 2 | 6 | 11 | 16 | 21 | 29 |
| EPS in Rs | 1.02 | 1.11 | 4.55 | 6.08 | 5.11 | 11.18 | 4.76 | 5.04 | 14.30 | 23.85 | 33.22 | 44.07 | 61.21 |
| Dividend Payout % | -0% | -0% | 13% | 10% | 12% | 6% | 14% | 14% | 5% | 3% | 2% | 2% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 100.00% | 100.00% | -50.00% | 0.00% | 200.00% | 83.33% | 45.45% | 31.25% |
| Change in YoY Net Profit Growth (%) | 0.00% | 100.00% | 0.00% | -150.00% | 50.00% | 200.00% | -116.67% | -37.88% | -14.20% |
Fredun Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 34% |
| 5 Years: | 32% |
| 3 Years: | 27% |
| TTM: | 36% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 54% |
| 5 Years: | 61% |
| 3 Years: | 49% |
| TTM: | 35% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 41% |
| 3 Years: | 4% |
| 1 Year: | 64% |
| Return on Equity | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 13% |
| 3 Years: | 15% |
| Last Year: | 16% |
Last Updated: September 5, 2025, 3:30 pm
Balance Sheet
Last Updated: December 4, 2025, 2:53 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 3 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 |
| Reserves | 0 | 0 | 1 | 2 | 19 | 35 | 37 | 39 | 64 | 92 | 117 | 137 | 153 |
| Borrowings | 7 | 9 | 16 | 21 | 10 | 19 | 35 | 40 | 53 | 87 | 106 | 166 | 171 |
| Other Liabilities | 8 | 11 | 24 | 30 | 47 | 47 | 65 | 79 | 66 | 74 | 81 | 179 | 136 |
| Total Liabilities | 18 | 23 | 43 | 56 | 79 | 105 | 141 | 162 | 187 | 257 | 308 | 487 | 464 |
| Fixed Assets | 7 | 8 | 15 | 16 | 16 | 31 | 31 | 30 | 32 | 39 | 47 | 53 | 65 |
| CWIP | 0 | 1 | 0 | 4 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 |
| Other Assets | 11 | 14 | 29 | 36 | 52 | 74 | 110 | 131 | 155 | 218 | 260 | 433 | 397 |
| Total Assets | 18 | 23 | 43 | 56 | 79 | 105 | 141 | 162 | 187 | 257 | 308 | 487 | 464 |
Below is a detailed analysis of the balance sheet data for Fredun Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 5.00 Cr..
- For Reserves, as of Sep 2025, the value is 153.00 Cr.. The value appears strong and on an upward trend. It has increased from 137.00 Cr. (Mar 2025) to 153.00 Cr., marking an increase of 16.00 Cr..
- For Borrowings, as of Sep 2025, the value is 171.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 166.00 Cr. (Mar 2025) to 171.00 Cr., marking an increase of 5.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 136.00 Cr.. The value appears to be improving (decreasing). It has decreased from 179.00 Cr. (Mar 2025) to 136.00 Cr., marking a decrease of 43.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 464.00 Cr.. The value appears to be improving (decreasing). It has decreased from 487.00 Cr. (Mar 2025) to 464.00 Cr., marking a decrease of 23.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 65.00 Cr.. The value appears strong and on an upward trend. It has increased from 53.00 Cr. (Mar 2025) to 65.00 Cr., marking an increase of 12.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
- For Other Assets, as of Sep 2025, the value is 397.00 Cr.. The value appears to be declining and may need further review. It has decreased from 433.00 Cr. (Mar 2025) to 397.00 Cr., marking a decrease of 36.00 Cr..
- For Total Assets, as of Sep 2025, the value is 464.00 Cr.. The value appears to be declining and may need further review. It has decreased from 487.00 Cr. (Mar 2025) to 464.00 Cr., marking a decrease of 23.00 Cr..
However, the Borrowings (171.00 Cr.) are higher than the Reserves (153.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -6.00 | -7.00 | -12.00 | -18.00 | -4.00 | -9.00 | -27.00 | -32.00 | -39.00 | -59.00 | -68.00 | -111.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 59 | 75 | 98 | 131 | 94 | 67 | 126 | 112 | 148 | 46 | 68 | 142 |
| Inventory Days | 107 | 102 | 140 | 68 | 170 | 249 | 227 | 242 | 96 | 264 | 246 | 265 |
| Days Payable | 152 | 167 | 221 | 224 | 360 | 205 | 208 | 215 | 101 | 104 | 88 | 160 |
| Cash Conversion Cycle | 14 | 11 | 17 | -24 | -96 | 110 | 145 | 139 | 144 | 205 | 225 | 247 |
| Working Capital Days | -44 | -54 | -44 | -39 | 42 | 66 | 65 | 116 | 126 | 97 | 92 | 76 |
| ROCE % | 14% | 14% | 25% | 18% | 16% | 21% | 10% | 10% | 13% | 18% | 17% | 19% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 44.83 | 33.66 | 24.13 | 11.28 | 5.05 |
| Diluted EPS (Rs.) | 44.83 | 33.32 | 22.93 | 11.28 | 5.05 |
| Cash EPS (Rs.) | 53.49 | 41.32 | 30.04 | 19.16 | 10.07 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 299.47 | 258.49 | 212.64 | 153.54 | 107.96 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 299.47 | 258.49 | 212.64 | 153.54 | 107.96 |
| Dividend / Share (Rs.) | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 |
| Revenue From Operations / Share (Rs.) | 961.13 | 740.88 | 606.04 | 506.38 | 335.60 |
| PBDIT / Share (Rs.) | 116.69 | 82.78 | 65.31 | 34.80 | 26.41 |
| PBIT / Share (Rs.) | 107.27 | 74.70 | 59.11 | 29.93 | 21.39 |
| PBT / Share (Rs.) | 59.87 | 45.65 | 38.63 | 19.40 | 8.04 |
| Net Profit / Share (Rs.) | 44.07 | 33.25 | 23.84 | 14.29 | 5.05 |
| PBDIT Margin (%) | 12.14 | 11.17 | 10.77 | 6.87 | 7.86 |
| PBIT Margin (%) | 11.16 | 10.08 | 9.75 | 5.91 | 6.37 |
| PBT Margin (%) | 6.22 | 6.16 | 6.37 | 3.83 | 2.39 |
| Net Profit Margin (%) | 4.58 | 4.48 | 3.93 | 2.82 | 1.50 |
| Return on Networth / Equity (%) | 14.71 | 12.86 | 11.21 | 9.30 | 4.67 |
| Return on Capital Employeed (%) | 31.78 | 24.93 | 17.72 | 11.71 | 11.35 |
| Return On Assets (%) | 4.27 | 5.07 | 4.20 | 3.38 | 1.24 |
| Long Term Debt / Equity (X) | 0.06 | 0.10 | 0.50 | 0.61 | 0.67 |
| Total Debt / Equity (X) | 1.18 | 0.86 | 0.89 | 0.77 | 0.92 |
| Asset Turnover Ratio (%) | 1.14 | 1.23 | 1.24 | 1.29 | 0.90 |
| Current Ratio (X) | 1.31 | 1.54 | 2.04 | 2.07 | 1.50 |
| Quick Ratio (X) | 0.57 | 0.49 | 0.62 | 1.44 | 0.72 |
| Inventory Turnover Ratio (X) | 2.19 | 1.75 | 2.51 | 3.11 | 1.71 |
| Dividend Payout Ratio (NP) (%) | 1.58 | 2.09 | 2.88 | 4.89 | 13.30 |
| Dividend Payout Ratio (CP) (%) | 1.30 | 1.68 | 2.28 | 3.65 | 6.67 |
| Earning Retention Ratio (%) | 98.42 | 97.91 | 97.12 | 95.11 | 86.70 |
| Cash Earning Retention Ratio (%) | 98.70 | 98.32 | 97.72 | 96.35 | 93.33 |
| Interest Coverage Ratio (X) | 2.46 | 2.85 | 3.19 | 3.30 | 2.53 |
| Interest Coverage Ratio (Post Tax) (X) | 1.93 | 2.14 | 2.16 | 2.36 | 1.76 |
| Enterprise Value (Cr.) | 477.16 | 441.23 | 435.36 | 456.41 | 223.45 |
| EV / Net Operating Revenue (X) | 1.05 | 1.27 | 1.59 | 2.03 | 1.67 |
| EV / EBITDA (X) | 8.66 | 11.34 | 14.71 | 29.59 | 21.21 |
| MarketCap / Net Operating Revenue (X) | 0.69 | 0.96 | 1.28 | 1.81 | 1.38 |
| Retention Ratios (%) | 98.41 | 97.90 | 97.11 | 95.10 | 86.69 |
| Price / BV (X) | 2.23 | 2.77 | 3.66 | 5.96 | 4.29 |
| Price / Net Operating Revenue (X) | 0.69 | 0.96 | 1.28 | 1.81 | 1.38 |
| EarningsYield | 0.06 | 0.04 | 0.03 | 0.01 | 0.01 |
After reviewing the key financial ratios for Fredun Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 44.83. This value is within the healthy range. It has increased from 33.66 (Mar 24) to 44.83, marking an increase of 11.17.
- For Diluted EPS (Rs.), as of Mar 25, the value is 44.83. This value is within the healthy range. It has increased from 33.32 (Mar 24) to 44.83, marking an increase of 11.51.
- For Cash EPS (Rs.), as of Mar 25, the value is 53.49. This value is within the healthy range. It has increased from 41.32 (Mar 24) to 53.49, marking an increase of 12.17.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 299.47. It has increased from 258.49 (Mar 24) to 299.47, marking an increase of 40.98.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 299.47. It has increased from 258.49 (Mar 24) to 299.47, marking an increase of 40.98.
- For Dividend / Share (Rs.), as of Mar 25, the value is 0.70. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.70.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 961.13. It has increased from 740.88 (Mar 24) to 961.13, marking an increase of 220.25.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 116.69. This value is within the healthy range. It has increased from 82.78 (Mar 24) to 116.69, marking an increase of 33.91.
- For PBIT / Share (Rs.), as of Mar 25, the value is 107.27. This value is within the healthy range. It has increased from 74.70 (Mar 24) to 107.27, marking an increase of 32.57.
- For PBT / Share (Rs.), as of Mar 25, the value is 59.87. This value is within the healthy range. It has increased from 45.65 (Mar 24) to 59.87, marking an increase of 14.22.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 44.07. This value is within the healthy range. It has increased from 33.25 (Mar 24) to 44.07, marking an increase of 10.82.
- For PBDIT Margin (%), as of Mar 25, the value is 12.14. This value is within the healthy range. It has increased from 11.17 (Mar 24) to 12.14, marking an increase of 0.97.
- For PBIT Margin (%), as of Mar 25, the value is 11.16. This value is within the healthy range. It has increased from 10.08 (Mar 24) to 11.16, marking an increase of 1.08.
- For PBT Margin (%), as of Mar 25, the value is 6.22. This value is below the healthy minimum of 10. It has increased from 6.16 (Mar 24) to 6.22, marking an increase of 0.06.
- For Net Profit Margin (%), as of Mar 25, the value is 4.58. This value is below the healthy minimum of 5. It has increased from 4.48 (Mar 24) to 4.58, marking an increase of 0.10.
- For Return on Networth / Equity (%), as of Mar 25, the value is 14.71. This value is below the healthy minimum of 15. It has increased from 12.86 (Mar 24) to 14.71, marking an increase of 1.85.
- For Return on Capital Employeed (%), as of Mar 25, the value is 31.78. This value is within the healthy range. It has increased from 24.93 (Mar 24) to 31.78, marking an increase of 6.85.
- For Return On Assets (%), as of Mar 25, the value is 4.27. This value is below the healthy minimum of 5. It has decreased from 5.07 (Mar 24) to 4.27, marking a decrease of 0.80.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 0.2. It has decreased from 0.10 (Mar 24) to 0.06, marking a decrease of 0.04.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.18. This value exceeds the healthy maximum of 1. It has increased from 0.86 (Mar 24) to 1.18, marking an increase of 0.32.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.14. It has decreased from 1.23 (Mar 24) to 1.14, marking a decrease of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 1.31. This value is below the healthy minimum of 1.5. It has decreased from 1.54 (Mar 24) to 1.31, marking a decrease of 0.23.
- For Quick Ratio (X), as of Mar 25, the value is 0.57. This value is below the healthy minimum of 1. It has increased from 0.49 (Mar 24) to 0.57, marking an increase of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.19. This value is below the healthy minimum of 4. It has increased from 1.75 (Mar 24) to 2.19, marking an increase of 0.44.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 1.58. This value is below the healthy minimum of 20. It has decreased from 2.09 (Mar 24) to 1.58, marking a decrease of 0.51.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 1.30. This value is below the healthy minimum of 20. It has decreased from 1.68 (Mar 24) to 1.30, marking a decrease of 0.38.
- For Earning Retention Ratio (%), as of Mar 25, the value is 98.42. This value exceeds the healthy maximum of 70. It has increased from 97.91 (Mar 24) to 98.42, marking an increase of 0.51.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 98.70. This value exceeds the healthy maximum of 70. It has increased from 98.32 (Mar 24) to 98.70, marking an increase of 0.38.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.46. This value is below the healthy minimum of 3. It has decreased from 2.85 (Mar 24) to 2.46, marking a decrease of 0.39.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.93. This value is below the healthy minimum of 3. It has decreased from 2.14 (Mar 24) to 1.93, marking a decrease of 0.21.
- For Enterprise Value (Cr.), as of Mar 25, the value is 477.16. It has increased from 441.23 (Mar 24) to 477.16, marking an increase of 35.93.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.05. This value is within the healthy range. It has decreased from 1.27 (Mar 24) to 1.05, marking a decrease of 0.22.
- For EV / EBITDA (X), as of Mar 25, the value is 8.66. This value is within the healthy range. It has decreased from 11.34 (Mar 24) to 8.66, marking a decrease of 2.68.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.69. This value is below the healthy minimum of 1. It has decreased from 0.96 (Mar 24) to 0.69, marking a decrease of 0.27.
- For Retention Ratios (%), as of Mar 25, the value is 98.41. This value exceeds the healthy maximum of 70. It has increased from 97.90 (Mar 24) to 98.41, marking an increase of 0.51.
- For Price / BV (X), as of Mar 25, the value is 2.23. This value is within the healthy range. It has decreased from 2.77 (Mar 24) to 2.23, marking a decrease of 0.54.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.69. This value is below the healthy minimum of 1. It has decreased from 0.96 (Mar 24) to 0.69, marking a decrease of 0.27.
- For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.06, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fredun Pharmaceuticals Ltd:
- Net Profit Margin: 4.58%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 31.78% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 14.71% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.93
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.57
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 27.4 (Industry average Stock P/E: 50.39)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.18
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 4.58%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | URMI ESTATE, 11th Floor, Mumbai Maharashtra 400013 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr.(Mrs.) Daulat N Medhora | Chairman & Jt. M. D |
| Mr. Fredun Medhora | Managing Director & CFO |
| Mrs. Daisy D�souza | Ind. Non-Executive Director |
| Mr. Anshu Agarwal | Ind. Non-Executive Director |
| Dr. Rohinton Kanga | Ind. Non-Executive Director |
| Dr. Aspi Raimalwala | Ind. Non-Executive Director |
| Mrs. Sonal Desai | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Fredun Pharmaceuticals Ltd?
Fredun Pharmaceuticals Ltd's intrinsic value (as of 21 January 2026) is ₹1547.95 which is 5.09% higher the current market price of ₹1,473.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹790 Cr. market cap, FY2025-2026 high/low of ₹1,999/635, reserves of ₹153 Cr, and liabilities of ₹464 Cr.
What is the Market Cap of Fredun Pharmaceuticals Ltd?
The Market Cap of Fredun Pharmaceuticals Ltd is 790 Cr..
What is the current Stock Price of Fredun Pharmaceuticals Ltd as on 21 January 2026?
The current stock price of Fredun Pharmaceuticals Ltd as on 21 January 2026 is ₹1,473.
What is the High / Low of Fredun Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Fredun Pharmaceuticals Ltd stocks is ₹1,999/635.
What is the Stock P/E of Fredun Pharmaceuticals Ltd?
The Stock P/E of Fredun Pharmaceuticals Ltd is 27.4.
What is the Book Value of Fredun Pharmaceuticals Ltd?
The Book Value of Fredun Pharmaceuticals Ltd is 334.
What is the Dividend Yield of Fredun Pharmaceuticals Ltd?
The Dividend Yield of Fredun Pharmaceuticals Ltd is 0.05 %.
What is the ROCE of Fredun Pharmaceuticals Ltd?
The ROCE of Fredun Pharmaceuticals Ltd is 18.9 %.
What is the ROE of Fredun Pharmaceuticals Ltd?
The ROE of Fredun Pharmaceuticals Ltd is 15.8 %.
What is the Face Value of Fredun Pharmaceuticals Ltd?
The Face Value of Fredun Pharmaceuticals Ltd is 10.0.